New funding will strengthen the Colton Consortium for Autoimmunity, a research network running across UPENN, NYU, Yale, and TAU

The Colton Consortium for Autoimmunity based at the University of Pennsylvania, last week announced a new $15 million, three-year investment from the Colton Foundation to strengthen scientific leadership, expand faculty expertise, and advance collaborative research to accelerate breakthroughs in autoimmune disease across its partner institutions at New York University, Tel Aviv University, and Yale University.

Autoimmune diseases affect millions worldwide and remain among the most complex conditions to diagnose, treat, and prevent. While advances in immunology have deepened our understanding of disease mechanisms, many conditions still lack effective therapies. At the same time, converging progress across academia, clinical research, and biopharma has created an ecosystem with transformative opportunities—one where coordinated investment and collaboration can translate discovery into meaningful advances for patients.

A Global Partnership for Autoimmune Research

The Colton Consortium for Autoimmunity is a global, multi-institutional research partnership uniting leading academic medical centers—including the University of Pennsylvania, New York University, Yale University, and Tel Aviv University—in a coordinated effort to transform the understanding, diagnosis, and treatment of autoimmune diseases. Through sustained philanthropic investment and a highly integrated collaborative model, the Consortium advances high-impact science that spans discovery research, translational studies, and clinical application, with the shared goal of improving outcomes for patients worldwide. The Consortium is made possible through the generosity of the Colton Foundation, led by Judy and Stewart Colton.

Strengthening Collaboration Across Institutions

This investment strengthens the Consortium’s ability to operate as an integrated, high-performing research network—supporting work that no single institution could accomplish alone. This new investment supports three core pillars: advancing faculty recruitment across institutions, accelerating cross-consortium research collaboration and strengthening leadership and research infrastructure. As the Consortium enters its next phase with this new $15 million investment, Colton investigators are well positioned to capitalize on a strong foundation and lead new advances in autoimmune research.

Uri Nevo, PhD, Director of the Colton Center for Autoimmunity at Tel Aviv University: “This generous donation enables Tel Aviv University, together with its clinical partners in hospitals and healthcare organizations across Israel, to establish collaborative partnerships with Colton institutions in the United States. Together, we will lead innovative research initiatives aimed at advancing the understanding and treatment of autoimmune diseases. The approved projects will include not only clinical and biological research, but also data-driven studies and studies designed to build the engineering and computational infrastructure necessary for improved diagnosis and treatment”.